Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9C7Z

Hallucinated C3 protein assembly HALC3_919

Summary for 9C7Z
Entry DOI10.2210/pdb9c7z/pdb
DescriptorHALC3_919, TETRAETHYLENE GLYCOL (3 entities in total)
Functional Keywordstrimer, hallucination, de novo, de novo protein
Biological sourcesynthetic construct
Total number of polymer chains2
Total formula weight16350.76
Authors
Ragotte, R.,Bera, A.,Milles, L.F.,Wicky, B.I.M.,Baker, D. (deposition date: 2024-06-11, release date: 2025-05-21, Last modification date: 2025-12-10)
Primary citationRagotte, R.J.,Tortorici, M.A.,Catanzaro, N.J.,Addetia, A.,Coventry, B.,Froggatt, H.M.,Lee, J.,Stewart, C.,Brown, J.T.,Goreshnik, I.,Sims, J.N.,Milles, L.F.,Wicky, B.I.M.,Glogl, M.,Gerben, S.,Kang, A.,Bera, A.K.,Sharkey, W.,Schafer, A.,Harkema, J.R.,Baric, R.S.,Baker, D.,Veesler, D.
Designed miniproteins potently inhibit and protect against MERS-CoV.
Cell Rep, 44:115760-115760, 2025
Cited by
PubMed Abstract: Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic pathogen with a 36% case-fatality rate in humans. No vaccines or specific therapeutics are currently approved for use in humans or the camel host reservoir. Here, we computationally designed monomeric and homo-oligomeric miniproteins that bind with high affinity to the MERS-CoV spike (S) glycoprotein, the main target of neutralizing antibodies and vaccine development. We show that these miniproteins broadly neutralize a panel of MERS-CoV S variants, spanning the known antigenic diversity of this pathogen, by targeting a conserved site in the receptor-binding domain (RBD). The miniproteins directly compete with binding of the dipeptidylpeptidase 4 (DPP4) receptor to MERS-CoV S, thereby blocking viral attachment to the host entry receptor and subsequent membrane fusion. Intranasal administration of a lead miniprotein provides prophylactic protection against stringent MERS-CoV challenge in mice, motivating its future clinical development as a next-generation countermeasure against this virus with pandemic potential.
PubMed: 40450691
DOI: 10.1016/j.celrep.2025.115760
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.1 Å)
Structure validation

246031

数据于2025-12-10公开中

PDB statisticsPDBj update infoContact PDBjnumon